首页> 外文期刊>Digestive Diseases and Sciences >Osteopontin Biomarker in Inflammatory Bowel Disease, Animal Models and Target for Drug Discovery
【24h】

Osteopontin Biomarker in Inflammatory Bowel Disease, Animal Models and Target for Drug Discovery

机译:炎症性肠病中的骨桥蛋白生物标志物,动物模型和药物发现靶标

获取原文
获取原文并翻译 | 示例
       

摘要

Inflammatory bowel disease (IBD) is an immune-mediated disease caused by abnormal mucosal T-cell response to bacteria in the intestinal lumen. In Crohn's disease (CD), mucosal T cells exhibit the TH1 phenotype, whereas ulcerative colitis (UC) is believed to have a TH2 phenotype [1]. In the absence of a single test, calculating disease activity in IBD remains a complicated task. An accurate and reliable marker for measuring CD or UC activity for routine clinical practice and in clinical trials has to be based on clinical judgment of histologic and endoscopic imaging. Therefore, validated accurate and objective measures of inflammatory activity in IBD using a reliable, non-invasive biomarker is needed [2]. Proteonome bio-markers are used in the diagnostics of IBD, but they are expensive and not all of them are validated [3].
机译:炎症性肠病(IBD)是由肠腔内细菌对细菌的粘膜T细胞异常反应引起的一种免疫介导的疾病。在克罗恩氏病(CD)中,粘膜T细胞表现出TH1表型,而溃疡性结肠炎(UC)被认为具有TH2表型[1]。在没有单一测试的情况下,计算IBD中的疾病活动仍然是一项复杂的任务。用于常规临床实践和临床试验中测量CD或UC活性的准确可靠的标记物必须基于组织学和内窥镜成像的临床判断。因此,需要使用可靠的,非侵入性的生物标志物对IBD中炎性活性进行准确而客观的验证[2]。蛋白质组生物标志物用于IBD的诊断,但价格昂贵,且并非所有标志物都经过验证[3]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号